Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2018 16:30 ET | Source: Brainsway Ltd.

Brainsway Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Increased market demand and new leasing model continue to generate significant sales growth Total minimum committed revenue projection is record $27 million for year-end 2017, up 142% versus...
March 19, 2018 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018

CARMIEL, Israel, March 19, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
March 15, 2018 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference

CARMIEL, Israel, March 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
March 14, 2018 07:48 ET | Source: Frutarom, Ltd.

Second Acquisition for Frutarom in 2018: Frutarom Deepens and Expands Its Penetration into Latin America in the Flavors and Fragrances Arena

Frutarom Acquires 70% of the Argentinian Flavors & Fragrances Group Meroar for US$ 11.2 million Frutarom's Entrance into the Argentinian Market will Open Up Significant Cross Selling...
March 13, 2018 09:00 ET | Source: Exalenz Bioscience Ltd.

Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients

MODI'IN, Israel and MANASQUAN, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
March 13, 2018 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of Patients No Anti-Drug Antibodies Detected CARMIEL, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- Protalix...
March 12, 2018 09:00 ET | Source: Exalenz Bioscience Ltd.

Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results

- 2017 revenue increased 127% to $9.5 million, compared with $4.2 million in 2016 - - Fourth quarter 2017 revenue increased 161% compared with same period in 2016 - MODI’IN, Israel and MANASQUAN,...
March 09, 2018 08:00 ET | Source: Exalenz Bioscience Ltd.

Exalenz Bioscience to Participate in Upcoming Investor Conferences

MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
March 08, 2018 10:15 ET | Source: Backbone Hosting Solutions Inc.

Bitfarms Establishes Several Computing Centres in Sherbrooke, Outlining a $250M Investment and 250 New Jobs

TEL AVIV, Israel and MONTREAL, March 08, 2018 (GLOBE NEWSWIRE) -- Blockchain Mining Ltd. (“BLCM” or the “Company”) (TASE:BLCM) (OTC:BITFY) is pleased to announce that Backbone Hosting Solutions...
March 07, 2018 18:08 ET | Source: Backbone Hosting Solutions Inc.

Backbone Hosting Solutions Inc. (Bitfarms) Announces the Appointment of Wes Fulford as New Chief Executive Officer

TEL AVIV, Israel and MONTREAL, March 07, 2018 (GLOBE NEWSWIRE) -- Blockchain Mining Ltd. (“BLCM” or the “Company”) (TASE:BLCM) (OTC:BITFY) is pleased to announce that Backbone Hosting Solutions...